dc.contributor.author | Schroeder, BA | |
dc.contributor.author | Kohli, K | |
dc.contributor.author | O'Malley, RB | |
dc.contributor.author | Kim, TS | |
dc.contributor.author | Jones, RL | |
dc.contributor.author | Pierce, RH | |
dc.contributor.author | Pollack, SM | |
dc.coverage.spatial | United States | |
dc.date.accessioned | 2022-09-02T14:08:44Z | |
dc.date.available | 2022-09-02T14:08:44Z | |
dc.date.issued | 2020-01-01 | |
dc.identifier | ARTN 1710064 | |
dc.identifier | 1710064 | |
dc.identifier.citation | OncoImmunology, 2020, 9 (1), pp. 1710064 - | en_US |
dc.identifier.issn | 2162-4011 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/5398 | |
dc.identifier.eissn | 2162-402X | |
dc.identifier.eissn | 2162-402X | |
dc.identifier.doi | 10.1080/2162402X.2019.1710064 | |
dc.description.abstract | Gastrointestinal stromal tumor (GIST) is a devastating disease, especially in the setting of metastasis. The natural progression of GIST has been significantly altered by the development of small molecule tyrosine kinase inhibitors (TKIs), including imatinib, sunitinib, and regorafenib, all of which are FDA approved. However, TKIs are not always well-tolerated, and the refractory disease continues to be a problem. For these reasons, alternative treatments are needed. In this report, we discuss a patient with metastatic wild-type (WT) GIST refractory to multiple TKIs, but with a durable clinical response to the anti-programmed cell death protein 1 (PD-1) antibody, nivolumab. This report suggests that continued research evaluating checkpoint inhibitors in GIST is warranted. | |
dc.format | Electronic-eCollection | |
dc.format.extent | 1710064 - | |
dc.language | eng | |
dc.language.iso | eng | en_US |
dc.publisher | TAYLOR & FRANCIS INC | en_US |
dc.relation.ispartof | OncoImmunology | |
dc.rights.uri | https://creativecommons.org/licenses/by-nc/4.0 | en_US |
dc.subject | GIST | |
dc.subject | Imatinib | |
dc.subject | Metastatic | |
dc.subject | Nivolumab | |
dc.subject | PD-1 | |
dc.subject | PD-L1 | |
dc.subject | Refractory | |
dc.subject | Sarcoma | |
dc.subject | Wild-Type | |
dc.subject | Drug Resistance, Neoplasm | |
dc.subject | Gastrointestinal Neoplasms | |
dc.subject | Gastrointestinal Stromal Tumors | |
dc.subject | Humans | |
dc.subject | Nivolumab | |
dc.subject | Protein Kinase Inhibitors | |
dc.title | Durable tumor regression in highly refractory metastatic KIT/PDGFRA wild-type GIST following treatment with nivolumab. | en_US |
dc.type | Journal Article | |
dcterms.dateAccepted | 2019-12-05 | |
dc.date.updated | 2022-09-02T14:08:00Z | |
rioxxterms.version | VoR | en_US |
rioxxterms.versionofrecord | 10.1080/2162402X.2019.1710064 | en_US |
rioxxterms.licenseref.startdate | 2020-01-01 | |
rioxxterms.type | Journal Article/Review | en_US |
pubs.author-url | https://www.ncbi.nlm.nih.gov/pubmed/32002307 | |
pubs.issue | 1 | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Sarcoma Clinical Trials (R Jones) | |
pubs.organisational-group | /ICR/Primary Group/Royal Marsden Clinical Units | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Sarcoma Clinical Trials (R Jones)/Sarcoma Clinical Trials (R Jones) (hon.) | |
pubs.publication-status | Published online | |
pubs.publisher-url | http://dx.doi.org/10.1080/2162402x.2019.1710064 | |
pubs.volume | 9 | |
dc.contributor.icrauthor | Jones, Robin | |
icr.provenance | Deposited by Mr Arek Surman on 2022-09-02. Deposit type is initial. No. of files: 1. Files: Durable tumor regression in highly refractory metastatic iKITPDGFRAi wild-type GIST following treatment with nivolumab.pdf | |